Cargando…

NK Cell-Based Glioblastoma Immunotherapy

Glioblastoma (GB) is the most aggressive and most common malignant primary brain tumor diagnosed in adults. GB shows a poor prognosis and, unfortunately, current therapies are unable to improve its clinical outcome, imposing the need for innovative therapeutic approaches. The main reason for the poo...

Descripción completa

Detalles Bibliográficos
Autores principales: Golán, Irene, Rodríguez de la Fuente, Laura, Costoya, Jose A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315402/
https://www.ncbi.nlm.nih.gov/pubmed/30567306
http://dx.doi.org/10.3390/cancers10120522
_version_ 1783384285985636352
author Golán, Irene
Rodríguez de la Fuente, Laura
Costoya, Jose A.
author_facet Golán, Irene
Rodríguez de la Fuente, Laura
Costoya, Jose A.
author_sort Golán, Irene
collection PubMed
description Glioblastoma (GB) is the most aggressive and most common malignant primary brain tumor diagnosed in adults. GB shows a poor prognosis and, unfortunately, current therapies are unable to improve its clinical outcome, imposing the need for innovative therapeutic approaches. The main reason for the poor prognosis is the great cell heterogeneity of the tumor mass and its high capacity for invading healthy tissues. Moreover, the glioblastoma microenvironment is capable of suppressing the action of the immune system through several mechanisms such as recruitment of cell modulators. Development of new therapies that avoid this immune evasion could improve the response to the current treatments for this pathology. Natural Killer (NK) cells are cellular components of the immune system more difficult to deceive by tumor cells and with greater cytotoxic activity. Their use in immunotherapy gains strength because they are a less toxic alternative to existing therapy, but the current research focuses on mimicking the NK attack strategy. Here, we summarize the most recent studies regarding molecular mechanisms involved in the GB and immune cells interaction and highlight the relevance of NK cells in the new therapeutic challenges.
format Online
Article
Text
id pubmed-6315402
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63154022019-01-09 NK Cell-Based Glioblastoma Immunotherapy Golán, Irene Rodríguez de la Fuente, Laura Costoya, Jose A. Cancers (Basel) Review Glioblastoma (GB) is the most aggressive and most common malignant primary brain tumor diagnosed in adults. GB shows a poor prognosis and, unfortunately, current therapies are unable to improve its clinical outcome, imposing the need for innovative therapeutic approaches. The main reason for the poor prognosis is the great cell heterogeneity of the tumor mass and its high capacity for invading healthy tissues. Moreover, the glioblastoma microenvironment is capable of suppressing the action of the immune system through several mechanisms such as recruitment of cell modulators. Development of new therapies that avoid this immune evasion could improve the response to the current treatments for this pathology. Natural Killer (NK) cells are cellular components of the immune system more difficult to deceive by tumor cells and with greater cytotoxic activity. Their use in immunotherapy gains strength because they are a less toxic alternative to existing therapy, but the current research focuses on mimicking the NK attack strategy. Here, we summarize the most recent studies regarding molecular mechanisms involved in the GB and immune cells interaction and highlight the relevance of NK cells in the new therapeutic challenges. MDPI 2018-12-18 /pmc/articles/PMC6315402/ /pubmed/30567306 http://dx.doi.org/10.3390/cancers10120522 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Golán, Irene
Rodríguez de la Fuente, Laura
Costoya, Jose A.
NK Cell-Based Glioblastoma Immunotherapy
title NK Cell-Based Glioblastoma Immunotherapy
title_full NK Cell-Based Glioblastoma Immunotherapy
title_fullStr NK Cell-Based Glioblastoma Immunotherapy
title_full_unstemmed NK Cell-Based Glioblastoma Immunotherapy
title_short NK Cell-Based Glioblastoma Immunotherapy
title_sort nk cell-based glioblastoma immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315402/
https://www.ncbi.nlm.nih.gov/pubmed/30567306
http://dx.doi.org/10.3390/cancers10120522
work_keys_str_mv AT golanirene nkcellbasedglioblastomaimmunotherapy
AT rodriguezdelafuentelaura nkcellbasedglioblastomaimmunotherapy
AT costoyajosea nkcellbasedglioblastomaimmunotherapy